Medtronic rolls out MiniMed 780G insulin pump system with Instinct sensor in US

GALWAY, Ireland – Medtronic has announced the broad U.S. commercial launch of the MiniMed 780G insulin pump system integrated with the Instinct sensor, made by Abbott and designed exclusively for MiniMed systems. The Instinct sensor is based on Abbott's most advanced continuous glucose monitoring (CGM) technology, featuring a small discreet sensor with a wear time of up to 15 days. When paired with the MiniMed 780G system, the Instinct sensor provides real-time glucose readings, which the system uses to automate insulin adjustments every five minutes. "This milestone marks an important next step in our work to bring the proven clinical outcomes of our MiniMed 780G system to more people living with diabetes," said Que Dallara, EVP and president of Medtronic Diabetes. "With this launch, we're expanding a smart dosing ecosystem built for choice, so every person can find a solution that fits their life. We exist to make life with diabetes easier and more predictable, so people living with diabetes can enjoy greater freedom and better health every day. Our goal is to deliver confidence and peace of mind, so everyone – including loved ones – can live boldly without compromise." In September, Medtronic received clearance from the U.S. Food and Drug Administration (FDA) for its SmartGuard algorithm as an interoperable automated glycemic controller (iAGC), enabling integration with Abbott’s Instinct sensor for Type 1 diabetes. The company has also received approval of the MiniMed 780G system for use in adults 18-plus with insulin-requiring Type 2 diabetes.